|1.||Rudick, R A: 14 articles (06/2011 - 12/2000)|
|2.||Kappos, Ludwig: 10 articles (10/2015 - 10/2007)|
|3.||Rudick, Richard A: 10 articles (11/2014 - 07/2004)|
|4.||Weinstock-Guttman, Bianca: 9 articles (04/2015 - 09/2005)|
|5.||Barkhof, Frederik: 8 articles (06/2014 - 10/2004)|
|6.||Weinstock-Guttman, B: 8 articles (08/2012 - 03/2000)|
|7.||Kappos, L: 8 articles (03/2011 - 11/2002)|
|8.||Comi, Giancarlo: 7 articles (06/2014 - 10/2004)|
|9.||O'Connor, Paul: 7 articles (05/2014 - 11/2003)|
|10.||Panzara, Michael A: 7 articles (11/2012 - 03/2006)|
03/01/2006 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of three double-blind placebo-controlled clinical trials (Early Treatment of Multiple Sclerosis and Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study and BENEFIT) support this conclusion."
06/01/2000 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study support this conclusion."
09/28/2000 - "Initiating treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis."
06/01/2012 - "This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. "
08/01/2006 - "Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis."
|2.||Relapsing-Remitting Multiple Sclerosis
01/01/2005 - "Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. "
01/01/2005 - "Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). "
10/01/1999 - "The aim of the study was to evaluate the efficacy of interferon beta-1a (IFN-beta-1a) and beta-1b (IFN-beta-1b) in clinical practice for the treatment of relapsing-remitting multiple sclerosis (RR MS). "
03/01/2015 - "A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis."
01/01/2015 - "Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 μg every two or four weeks has been studied in relapsing-remitting multiple sclerosis (RRMS) patients in the pivotal Phase 3 ADVANCE trial. "
|3.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
02/23/2010 - "Because IM interferon beta-1a (IM IFNbeta-1a) is an effective and safe treatment for MS, we conducted a dose-ranging efficacy study of IFNbeta-1a in patients with CIDP. "
07/13/1999 - "To test the safety and efficacy of interferon beta-1a (IFN-beta) in treatment-resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). "
07/13/1999 - "Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy."
02/23/2010 - "Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy."
04/01/2003 - "Interferon beta-1a as an investigational treatment for CIDP."
|4.||Crohn Disease (Crohn's Disease)
01/01/2009 - "Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study."
08/01/2010 - "Pivotal clinical trials included: Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM), Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis (SENTINEL), Efficacy of Natalizumab as Active Crohn's Therapy (ENACT)-1 and 2 and Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE). "
01/01/2007 - "Recently, two patients with multiple sclerosis treated with natalizumab in combination with interferon beta-1a and one patient with Crohn's disease treated with natalizumab in combination with azathioprine developed progressive multifocal leukoencephalopathy (PML) resulting in two patient deaths. "
01/01/2006 - "Recently, two patients with multiple sclerosis treated with natalizumab in combination with interferon beta-1a and one patient with Crohn's disease treated with natalizumab in combination with azathioprine developed progressive multifocal leukoencephalopathy (PML) resulting in two patient deaths. "
07/01/2004 - "Local pain during REBIF injection is not due to acidic pH."
11/01/2007 - "Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b."
01/01/2008 - "A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis."
08/01/2006 - "A single-blind, placebo-controlled crossover study was conducted to evaluate the efficacy of EMLA cream in reducing the fear and pain associated with intramuscular (IM) injection during administration of interferon beta-1a to patients with multiple sclerosis. "
08/01/2006 - "Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis."
|1.||interferon beta 1a
|8.||interferon beta-1b (Betaseron)
|9.||copolymer 1 (glatiramer acetate)
|3.||Self Administration (Administration, Self)